Multigene tests in assessing and treating early endocrine-dependent breast cancer / 中华内分泌外科杂志

Detection of Oncotype DX and MammaPrint has been recommended by the American Society of Clinical 0ncology.For specific populations,such as early endocrine-dependent breast cancer,under the condition of sufficient evidence in the evidence-based medicine,we can choose genetic testing in combination with clinical pathologic factors to guide clinical treatment,which has reached the goal of micro combined with macro,more detailed division of the patients,and individualized treatment.